Skip Nav Destination
Drug Discovery
Protein Degradation with New Chemical Modalities
Edited by
Hilmar Weinmann;
Hilmar Weinmann
Janssen Pharmaceutica N.V., Belgium
Search for other works by this author on:
Craig Crews
Craig Crews
Yale University, USA
Search for other works by this author on:
Hardback ISBN:
978-1-78801-686-5
PDF ISBN:
978-1-83916-069-1
EPUB ISBN:
978-1-83916-077-6
Special Collection:
2020 ebook collection
Series:
Drug Discovery
No. of Pages:
358
Publication date:
07 Oct 2020
Book Chapter
Chapter 8: PROTAC Targeting BTK for the Treatment of Ibrutinib-resistant B-cell Malignancies
By
Yonghui Sun
;
Yonghui Sun
MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology
Tsinghua University
Beijing
100084
P.R. China
yrao@tsinghua.edu.cn
Search for other works by this author on:
Yu Rao
Yu Rao
MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology
Tsinghua University
Beijing
100084
P.R. China
yrao@tsinghua.edu.cn
Search for other works by this author on:
-
Published:07 Oct 2020
-
Special Collection: 2020 ebook collectionSeries: Drug Discovery
Citation
Y. Sun and Y. Rao, in Protein Degradation with New Chemical Modalities, ed. H. Weinmann and C. Crews, The Royal Society of Chemistry, 2020, ch. 8, pp. 147-166.
Download citation file:
This chapter covers the following sections – an introduction of Bruton’s tyrosine kinase (BTK) signaling module, an introduction of non-Hodgkin’s lymphoma and the development of BTK inhibitors followed by drug resistance and side effects, and lastly the development and prospect of BTK PROTACs.
You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Digital access
$64.60
